A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

211

Participants

Timeline

Start Date

December 29, 2022

Primary Completion Date

June 12, 2024

Study Completion Date

October 12, 2024

Conditions

T2DMType 2 Diabetes Mellitus

Interventions

DRUG

Ecnoglutide

Subcutaneous Injection

DRUG

Placebo

Subcutaneous Injection with matched volume

Trial Locations (1)

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors

lead

Hangzhou Sciwind Biosciences Co., Ltd.

INDUSTRY